AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials

AstraZeneca and Daiichi Sankyo have reported updated data from the Phase I TROPION-PanTumor01 clinical trial, where their datopotamab deruxtecan (Dato-DXd) showed to offer encouraging responses in heavily pretreated metastatic triple-negative breast cancer (TNBC) patients.